Bristol-Myers Squibb Company
BMY
Positions held
Your positionsBMY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Bristol-Myers Squibb's strong revenue growth of 5.7% year-over-year indicates a solid demand for its products in the competitive pharmaceutical industry.
- In Q2 2026, the company reported a revenue of $12.973 billion, a 13% increase compared to the previous quarter.
- The operating margin improved to 31% in Q2 2026, up from 29.3% in Q1 2026.
- The company's current financial score indicates a 'Strong Sell' signal, reflecting potential challenges in the market.
- Bristol-Myers Squibb's net income dropped significantly to $1.087 billion in Q4 2025, down from $2.201 billion in Q3 2025.
- The operating margin for the year 2024 was only 12.2%, indicating a substantial decline in profitability.
Fundamentals
| Market cap | $121.70B | Enterprise value | $155.69B | Trailing P/E | 13.12 | Forward P/E | 9.02 |
| PEG | 16.62 | Price / book | 5.45 | Beta | 0.18 | Dividend yield | 4.23% |
| Revenue growth | 5.7% | Earnings growth | 153.1% | Gross margin | 71.7% | Operating margin | 34.4% |
| Profit margin | 18.9% | ROE | 46.6% | ROA | 10.7% | Debt / equity | 2.02 |
| Current ratio | 1.53 | Free cash flow | $8.11B | Analyst recommendation | buy | Mean target | $65.92 |
| 52w high | $68.64 | 52w low | $42.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $13.0B | $11.5B | $12.5B | $12.2B | $12.3B | — |
| Op margin | 31.0% | 29.3% | 22.5% | 29.8% | 30.8% | — |
| Net income | $3.3B | $2.7B | $1.1B | $2.2B | $1.3B | — |
| Gross margin | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | — |
| Gross profit | $9.2B | $8.1B | $8.4B | $8.8B | $8.9B | — |
| Operating income | $4.0B | $3.4B | $2.8B | $3.6B | $3.8B | — |
- Revenue +13% vs prior quarter ($13.0B vs $11.5B).
- Gross margin 71.3% (was 70.2% prior quarter).
- Operating margin expanded to 31%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B | $46.2B | — |
| Op margin | 28.5% | 12.2% | 18.2% | 19.7% | — |
| Net income | $7.1B | -$8.9B | $8.0B | $6.3B | — |
| Gross margin | 71.1% | 71.1% | 76.2% | 78.0% | — |
| Gross profit | $34.3B | $34.3B | $34.3B | $36.0B | — |
| Operating income | $13.7B | $5.9B | $8.2B | $9.1B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
2026-10-09 · What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?
2026-10-09 · BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $71
2026-10-09 · 2 Profitable Stocks to Target This Week and 1 We Find Risky
2026-10-09 · Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-09 · Should You Be Worried About Pfizer Stock?
2026-10-09 · What Is Going On With Regeneron Stock?
2026-10-08 · BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
2026-10-08 · Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
2026-10-08 · AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
2026-10-08 · What Would It Take For Amgen Stock To Move Higher?
Price (daily)
Full chart · RSI · MACD · patterns